Navigation Links
Poniard Pharmaceuticals Secures $20 Million Committed Equity Financing Facility
Date:2/23/2010

ts based on a number of factors, including risks and uncertainties inherent in the Company's business, including, but not limited to, the results and timing of the Company's discussions with the FDA; the potential safety, efficacy and commercial viability of picoplatin; the risk that the Company's additional analyses of data from clinical trials of picoplatin may produce negative or inconclusive results, or may be inconsistent with previously announced results or previously conducted trials; the Company's anticipated operating losses, need for future capital and ability to obtain future funding; the Company's ability to retain key personnel and enter into strategic partnerships on favorable terms, or at all; competition from third parties; the Company's ability to preserve and protect its intellectual property rights; the Company's dependence on third-party manufacturers, suppliers and other contractors; changes in technology, government regulation and general market conditions; the receipt and timing of any FDA and other required regulatory approvals, if any; and the risks and uncertainties described in the Company's current and periodic reports filed with the Securities and Exchange Commission (SEC), including the Company's Annual Report on Form 10-K for the year ended December 31, 2008, and its Quarterly Report on Form 10-Q for the period ended September 30, 2009. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this release. The Company undertakes no obligation to update any forward-looking statement to reflect new information, events or circumstances after the date of this release or to reflect the occurrence of unanticipated events.

SOU
'/>"/>

SOURCE Poniard Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Poniard Pharmaceuticals to Present at 12th Annual BIO CEO and Investor Conference
2. Poniard Pharmaceuticals Announces Management Changes and Reduction in Force
3. Poniard Pharmaceuticals Announces Phase 2 Trial of Picoplatin in Metastatic Colorectal Cancer Meets Primary Endpoint and Study Objectives
4. Poniard Pharmaceuticals Announces Updated Positive Clinical Data from Phase 2 Trial of Picoplatin in Colorectal Cancer and New Phase 1 Cardiac Safety Trial Results
5. Poniard Pharmaceuticals Announces Positive Cardiac Safety Data From Picoplatin Phase 1 Trial Supporting NDA Filing
6. Poniard Pharmaceuticals Announces Progression-Free Survival Data From Phase 2 Clinical Trial of Picoplatin in Metastatic Colorectal Cancer
7. Poniard Pharmaceuticals Reports First Quarter 2009 Financial Results and Provides a Corporate Update
8. Poniard Pharmaceuticals to Present New Data from Phase 2 Clinical Trials of Picoplatin in Multiple Tumor Types at the 45th Annual Meeting of the American Society of Clinical Oncology
9. Poniard Completes Patient Enrollment Target in Phase 3 SPEAR Trial of Picoplatin in Small Cell Lung Cancer
10. Poniard Pharmaceuticals Reports Fourth Quarter and Year End 2008 Financial Results and Provides a Corporate Update
11. Poniard Pharmaceuticals Announces Management Changes and Focus on Development and Commercialization of Picoplatin
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/5/2015)... QC , May 5, 2015 /CNW Telbec/ - ... Laval and known under the ... today the closing of the transaction previously announced on ... the issued and outstanding  shares of Orthoconcept (2008) inc.   ... issuing 500 000 common shares (TSXV: ERG) to the ...
(Date:5/5/2015)... EXTON, Pa. , May 5, 2015  The ... global leader in pharmacokinetic testing of drugs and safety ... Gum , Associate Director of Preclinical Studies, presented at ... in Vision and Ophthalmology (ARVO) in Denver, ... presentation was "Safety Assessment of a Novel, Cross-Linked, Bio-Absorbable ...
(Date:5/5/2015)... NIJMEGEN, the Netherlands , May ... company developing lower esophageal sphincter (LES) stimulation therapy ... positive safety and efficacy results. The results demonstrated ... heartburn and regurgitation and the "gold-standard" esophageal acid ... near-complete elimination of dependence on daily PPI medications. ...
Breaking Medicine Technology:Ergoresearch announces closing of the acquisition of 49% of the shares of Orthoconcept (2008) inc. 2Ergoresearch announces closing of the acquisition of 49% of the shares of Orthoconcept (2008) inc. 3Dr. Glen Gum of Absorption Systems Presents at The Association for Research in Vision and Ophthalmology (ARVO) Meeting 2Dr. Glen Gum of Absorption Systems Presents at The Association for Research in Vision and Ophthalmology (ARVO) Meeting 3Excellent three year results of EndoStim therapy for severe reflux disease presented at the SAGES Annual Meeting in Nashville. 2Excellent three year results of EndoStim therapy for severe reflux disease presented at the SAGES Annual Meeting in Nashville. 3
... (MARKET WIRE) -- July 06, ... <a target="_blank" href=,'http://studio.financialcontent.com/Engine?Account=iwire&PageName=QUOTE&Ticker=DORB"%3EDORB'>,http://studio.financialcontent.com/Engine?Account=iwire&PageName=QUOTE&Ticker=DORB">DORB ),("DOR" or ... the European Patent,Office has granted ... with claims related to,oral vaccination ...
... in The Lancet on TMC125, an Investigational ... /PRNewswire/ -- Data from two,ongoing Phase 3 ... adult patients with documented non-nucleoside reverse,transcriptase inhibitor ... undetectable viral load (defined as achieving,confirmed undetectable ...
Cached Medicine Technology:DOR BioPharma Announces Issuance of European Patent for Its Oral,Multivalent Botulinum Toxin Vaccine BT-VACC 2DOR BioPharma Announces Issuance of European Patent for Its Oral,Multivalent Botulinum Toxin Vaccine BT-VACC 3DOR BioPharma Announces Issuance of European Patent for Its Oral,Multivalent Botulinum Toxin Vaccine BT-VACC 4DOR BioPharma Announces Issuance of European Patent for Its Oral,Multivalent Botulinum Toxin Vaccine BT-VACC 5DOR BioPharma Announces Issuance of European Patent for Its Oral,Multivalent Botulinum Toxin Vaccine BT-VACC 6TMC125 Showed Significant Virologic Response at Week 24 in,Treatment-Experienced HIV Patients With NNRTI Resistance in Phase 3,Trials 2TMC125 Showed Significant Virologic Response at Week 24 in,Treatment-Experienced HIV Patients With NNRTI Resistance in Phase 3,Trials 3TMC125 Showed Significant Virologic Response at Week 24 in,Treatment-Experienced HIV Patients With NNRTI Resistance in Phase 3,Trials 4
(Date:5/6/2015)... May 06, 2015 The SGNY Group ... York City, announced today that it was named a ... a presentation video produced on behalf of Intarcia Therapeutics. ... category of motion graphics. , The competition sponsored by ... over 6000 entries from 22 countries. The competition ...
(Date:5/6/2015)... England (PRWEB) May 06, 2015 The ... with new drinks. Little Miracles organic tea and superfruit ... natural Panax ginseng and sweetened with agave, these delicious ... consumer movement that seeks healthier ways to hydrate. , ... Little Miracles invites people to raise a bottle of ...
(Date:5/5/2015)... May 05, 2015 With the FCPX LUT: ... quickly and easily add washed color grades to footage. A ... for modifying an image. The LUT changes every pixel's color ... comes with 90 washed CUBE LUT files. , This plugin ... can give any footage a washed look. , CUBE ...
(Date:5/5/2015)... (PRWEB) May 05, 2015 Beverly Hills Cosmetic ... health and beauty products to be sold at the offices ... in Beverly Hills, and worldwide through an online store ... to fill the gap between dental care and beauty with ... beautiful and youthful,” says Dr. Glosman. , Dr. Glosman’s ...
(Date:5/5/2015)... 2015 AxoGen, Inc. (NASDAQ: AXGN), ... $1.6 billion peripheral nerve repair market, reported record revenue ... 31, 2015 compared to $3.14 million in the year-ago ... our proprietary portfolio of nerve repair products - ... Protector – and our solid sales execution delivered another ...
Breaking Medicine News(10 mins):Health News:The SGNY Group Wins Platinum Hermes Creative Award 2Health News:Say Cheers to National Beverage Day with Little Miracles 2Health News:Pixel Film Studios Announced the Release of FCPX LUT Monochromatic 2Health News:Beverly Hills Dentist Arthur Glosman Launches New Dental Health And Beauty Product Line 2Health News:AxoGen, Inc. Reports 58% Year-Over-Year Revenue Growth for the 2015 First Quarter 2Health News:AxoGen, Inc. Reports 58% Year-Over-Year Revenue Growth for the 2015 First Quarter 3Health News:AxoGen, Inc. Reports 58% Year-Over-Year Revenue Growth for the 2015 First Quarter 4
... ... movies for presentations, demonstrations and training. Version 7.5 introduces TrakMouse™, a new technology that ... , ... July 9, 2009 -- NetPlay Software releases Instant Demo v7.5 , a Windows ...
... Hollywood impact radiation perception? Can we treat cancer with ... the radiation exposure our astronauts receive during space travel ... and other questions will be addressed at the 54th ... will take place July 13-16, 2009 in Minneapolis, MN, ...
... ... change the law regarding personal injury accidents, New York personal injury lawyer David Perecman weighs ... New York, New ... Authority (MTA) spends millions to pay for damages caused to riders., , , , ,Unfortunately ...
... MedClean Technologies, Inc. (OTC Bulletin Board: MCLN) announced today ... the Company,s existing Common Stock Purchase Warrants with Initial Exercise ... Warrants") for newly issued Common Stock Purchase Warrants with a ... one-half the original number of shares of our common stock, ...
... TROIS-RIVIERES, Quebec, July 8 The Narconon drug rehab program ... with drug related charges due to their addiction. "You ... drug addiction, and just one day gets caught by police ... representative of Narconon Trois-Rivieres. "This is an all too ...
... Today, the American Hospital Association, Federation of American Hospitals ... White House and Senate Finance Chairman Max Baucus (D-MT) ... Cost savings is an important goal, supported by Physician ... owned hospitals. As always, physician hospitals will shoulder their ...
Cached Medicine News:Health News:Instant Demo Screen Recorder Now With TrakMouse&#8482; Technology 2Health News:Health Physics Society 54th Annual Meeting 2Health News:As Lawsuits Hit the MTA, Personal Injury Lawyers Consider How Much is Too Much, or Too Little 2Health News:As Lawsuits Hit the MTA, Personal Injury Lawyers Consider How Much is Too Much, or Too Little 3Health News:MedClean Technologies Announces Results of Private Exchange Offer 2Health News:Drug Crimes in Canada Cause Continuing Problems for Small Communities 2Health News:Physician Hospitals of America Charges: Hospital Associations Bargain Away $155 Billion in Medicare Funding in Attempt to Destroy Physician Hospitals 2Health News:Physician Hospitals of America Charges: Hospital Associations Bargain Away $155 Billion in Medicare Funding in Attempt to Destroy Physician Hospitals 3
The uncemented hip joint prosthesis system....
The proximally modular S-ROM Total Hip System provides custom capability at non-custom prices and is competitive with conventional porous coated systems....
The Natural-Hip combines the surgical simplicity of a straight stem with many of the best features of an anatomic stem....
The Natural-Hip combines the surgical simplicity of a straight stem with many of the best features of an anatomic stem....
Medicine Products: